hort stature is one of the most common reasons of admissions to pediatric endocrinology departments. Laron syndrome is a very rare familial disorder with both autosomal recessive and autosomal dominant forms of inheritance. After definition of this genetic form of dwarfism by Zvi Laron and his colleagues in 1966, approximately 250 patients were identified worldwide.
1,2 Laron syndrome is characterized by marked short stature that results from lack of responsiveness to growth hormone (GH). GH levels are normal or increased. At the same time generation of insulin-like growth factor I fails because of GH receptor defects, abnormalities of GH signal transduction or primary defects of insulin-like growth factor I synthesis or secretion. 3 Cases of growth hormone insensitivity (GHI) and growth hormone deficiency share a common phenotype. Birth weights of patients are usually normal or near normal but birth length may be slightly decreased. The patients can present with hypoglycemia or prolonged jaundice in neonatal period. Postnatal growth is strikingly influenced and patients ordinarily apply due to severe growth failure. Craniofacial features of patients are prominent forehead, frontal bossing, craniofacial disproportion due to small facies, hypoplastic nasal bridge, and blue sclera. High-pitched voice is remarkable. Skeletal age is delayed but may be advanced relative to height age. Micropenis is another clinical finding of patients in childhood. Even with normal gonadotropin production, puberty is generally delayed for 3 to 7 years. 3 The combination of decreased serum concentrations of IGF-1 and IGFBP-3 plus increased serum concentrations of GH is highly suggestive of growth hormone insensitivity. These findings must be combined with inadequate response of increasing serum IGF-1 at least 15 ng/mL and IGFBP-3 concentrations at least 400 ng/mL to exogenous growth hormone. A scoring system was proposed for evaluation of short children for growth hormone insensitivity. 
GEÇEN SAYININ BİLMECE OLGUSUNUN YANITI
Pa ti ents co uld not be ne fit from GH the rapy be ca u se of IGF-1 generation failure. Pro duc ti on of IGF pep ti des by re com bi nant DNA tech no logy gives a chan ce to pa ti ents with growth hor mo ne insen si ti vity. Stu di es of IGF-1 tre at ment of GHI ha ve in di ca ted a per sis tent ef fect on growth ra te, alt hough he ight ve lo city re ma i ned slightly be low which was ac hi e ved in the first and se cond ye ars of tre atment, in the sub se qu ent ye ars. 5 We re por ted a ca se of growth hor mo ne in sensi ti vity (La ron syndro me) with cha rac te ris tic cli nic fe a tu res and la bo ra tory fin dings. This ra re di sor der must be con si de red es pe ci ally if the pa ti ents ha ve se ve re short sta tu re.
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